Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Filed Chapter 11
Quarterly results
Appointed director

OSCIENT PHARMACEUTICALS CORP (OSCI) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/12/2010 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/11/2010 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
07/28/2009 25-NSE Form 25-NSE --
07/13/2009 8-K Quarterly results
06/22/2009 8-K Other Events
06/16/2009 8-K Cost Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits
Docs: "Oscient Pharmaceuticals Discontinues Sales Force Promotion for ANTARA and FACTIVE"
06/15/2009 SC 13G/A Form SC 13G - Statement of acquisition of beneficial ownership by individuals [amend]
05/29/2009 SC 13G BB BIOVENTURES L P reports a
05/29/2009 4 BB BIOVENTURES L P (10% Owner) has filed a Form 4 on OSCIENT PHARMACEUTICALS CORP
05/26/2009 4 Form 4 - Statement of changes in beneficial ownership of securities
05/22/2009 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
Docs: "Oscient Pharmaceuticals Receives NASDAQ Letter Regarding Delay in Filing Form 10-Q Waltham, Mass., May 22, 2009 - Oscient Pharmaceuticals Corporation has received notification from the Listings Qualifications Department of The NASDAQ Stock Market LLC that since the Company has not filed its Form 10-Q for the period ended March 31, 2009, the Company is no longer in compliance with Marketplace Rule 5250. The Company has 60 calendar days, or until July 20, 2009, to submit a plan to regain compliance. Following such submission, NASDAQ may provide the Company with up to 180 calendar days from the filing's due date, or until November 11, 2009, to regain compliance. If NASDAQ does not accept the Company's plan to regain compliance, the Company will receive written notification of delisting from N..."
05/19/2009 SC 13G/A DellaCamera Capital Management, LLC reports a 3.6% stake in Oscient Pharmaceuticals Corporation.
05/18/2009 SC 13G/A ORBIMED ADVISORS LLC reports a 2.2% stake in Oscient Pharmaceuticals
05/15/2009 8-K Form 8-K -- Current report
05/13/2009 4 DellaCamera Capital Management, LLC (10% Owner) has filed a Form 4 on OSCIENT PHARMACEUTICALS CORP
05/12/2009 4 DellaCamera Capital Management, LLC (10% Owner) has filed a Form 4 on OSCIENT PHARMACEUTICALS CORP
05/01/2009 8-K Form 8-K -- Current report
04/29/2009 10-K/A Annual Report for the period ended December 31, 2008 [amend]
04/17/2009 4 DellaCamera Capital Management, LLC (10% Owner) has filed a Form 4 on OSCIENT PHARMACEUTICALS CORP
04/01/2009 4 DellaCamera Capital Management, LLC (10% Owner) has filed a Form 4 on OSCIENT PHARMACEUTICALS CORP
03/27/2009 8-K Form 8-K -- Current report
03/25/2009 10-K Annual Report for the period ended December 31, 2008
03/25/2009 8-K Quarterly results
Docs: "Oscient Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Financial Results - Conference call scheduled for Thursday, March 26 at 8:30 AM ET -",
"NASDAQ Extends Temporary Suspension of Bid Price and Market Value of Publicly Held Shares Requirements; Oscient Compliance Period Extended to October 6, 2009"
03/23/2009 8-K Form 8-K -- Current report
02/13/2009 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
02/13/2009 8-K Form 8-K -- Current report
02/13/2009 SC 13G/A Form SC 13G/A -- Statement of acquisition of beneficial ownership by individuals [amend]
02/05/2009 SC 13G ZAZOVE ASSOCIATES LLC reports a 15.9% stake in Oscient Pharmacuetical Corporation
02/03/2009 8-K Form 8-K -- Current report
02/03/2009 SC 13G/A RG CAPITAL MANAGEMENT LP reports a 6% stake in Oscient Pharmaceuticals Corporation
01/29/2009 SC 13G/A CITIGROUP INC reports a 6.1% stake in Oscient Pharmaceuticals Corporation
01/15/2009 3 GLG Partners LP (10% Owner) has filed a Form 3 on OSCIENT PHARMACEUTICALS CORP
01/15/2009 SC 13G GLG Partners LP reports a 10.6% stake in Oscient Pharmaceuticals Corporation
01/15/2009 8-K Other Events, Financial Statements and Exhibits
Docs: "Oscient Pharmaceuticals and Ethypharm SA File Lawsuit Against Lupin for Infringement of ANTARA Patent"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy